Publication details
Novinky v léčbě chronické hepatitidy C
| Title in English | News in the treatment of chronic hepatitis C |
|---|---|
| Authors | |
| Year of publication | 2013 |
| Type | Article in Periodical |
| Magazine / Source | Acta medicinae |
| MU Faculty or unit | |
| Citation | |
| Field | Epidemiology, infectious diseases and clinical immunology |
| Keywords | chronic hepatitis C virus; HCV; telaprevir; boceprevir |
| Attached files | |
| Description | In the last two years there has been a fundamental change in the treatment of chronic hepatitis C virus (HCV) infection. The base of this change is the commercial availability of protease inhibitors – telaprevir and boceprevir, administered in combination with pegylated interferon alpha and ribavirin for genotype 1 infection HCV therapy. In the following years, you can expect the gradual placing on the market of other drugs effective against HCV, and that different genotypes, which will be administered either in combination with pegylated interferon alpha and Ribavirin, or it will be a combination of only orally administered drugs: interferon (IFN)-free regimes. |